Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 10326
Country/Region: Uganda
Year: 2016
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $16,332,296 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,709,138
Care: TB/HIV (HVTB) $461,141
Care: Pediatric Care and Support (PDCS) $1,029,641
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $2,578,120
Testing: HIV Testing and Counseling (HVCT) $908,485
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $455,091
Treatment: Adult Treatment (HTXS) $7,637,851
Treatment: Pediatric Treatment (PDTX) $552,829
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD Age/Sex: <10 Female 2017 161
GEND_GBV_DSD Age/Sex: <10 Male 2017 97
GEND_GBV_DSD Age/Sex: 10-14 Female 2017 452
GEND_GBV_DSD Age/Sex: 10-14 Male 2017 97
GEND_GBV_DSD Age/Sex: 15-19 Female 2017 806
GEND_GBV_DSD Age/Sex: 15-19 male 2017 160
GEND_GBV_DSD Age/Sex: 20-24 Female 2017 809
GEND_GBV_DSD Age/Sex: 20-24 Male 2017 161
GEND_GBV_DSD Age/Sex: 25-49 Female 2017 323
GEND_GBV_DSD Age/Sex: 25-49 Male 2017 161
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 291
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 711
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 2,516
GEND_GBV_DSD Number of people receiving post-GBV care 2017 3,227
GEND_GBV_DSD Sum of Age/Sex Disaggregates 2017 807
HTC_TST_DSD Age/sex: <1 2017 4,308
HTC_TST_DSD Age/sex: 1-9 2017 14,207
HTC_TST_DSD Age/sex: 10-14 Female 2017 12,271
HTC_TST_DSD Age/sex: 10-14 Male 2017 12,269
HTC_TST_DSD Age/sex: 15-19 Female 2017 42,963
HTC_TST_DSD Age/sex: 15-19 Male 2017 64,607
HTC_TST_DSD Age/sex: 20-24 Female 2017 64,445
HTC_TST_DSD Age/sex: 20-24 Male 2017 96,914
HTC_TST_DSD Age/sex: 25-49 Female 2017 98,814
HTC_TST_DSD Age/sex: 25-49 Male 2017 148,596
HTC_TST_DSD Age/sex: 50+ Female 2017 8,590
HTC_TST_DSD Age/sex: 50+ Male 2017 12,918
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 21,530
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 21,525
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 214,812
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 323,035
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 580,902
HTC_TST_DSD Service Delivery Point (Facility): Index testing 2017 44,057
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 94,691
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 30,778
HTC_TST_DSD Service Delivery Point (Facility): Outpatient 2017 182,752
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 40,046
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 56,773
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 3,247
HTC_TST_DSD Service Delivery Point (Facility): VMMC 2017 128,558
HTC_TST_DSD Sum of Age/Sex disaggregates 2017 562,387
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 43,055
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 537,847
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 580,902
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 2017 367
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 2017 372
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 2017 1,472
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 2017 1,021
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Female 2017 2,208
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 2017 1,532
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Female 2017 3,383
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 2017 2,350
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Female 2017 292
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 2017 204
HTC_TST_DSD Test Result by Age: Positive: <1 2017 124
HTC_TST_DSD Test Result by Age: Positive: 1-9 2017 430
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 644
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 649
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 7,355
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 5,107
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 2,125
PMTCT_ART_DSD New on ART 2017 1,525
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 57,476
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 2,405
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 680
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 31
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 121
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 3,085
PMTCT_STAT_DSD By: Known positives at entry 2017 2,323
PMTCT_STAT_DSD By: Number of new positives identified 2017 1,533
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 58,948
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 57,476
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 3,856
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 25
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 609
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 32
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,110
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,776
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,776
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 6,421
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 642
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,926
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3,853
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 1,605
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 49,637
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 25,560
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 2,697
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 2,390
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 80,284
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 113
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,539
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 148
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,797
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,597
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 4,597
TX_CURR_DSD Age/Sex: <1 2017 204
TX_CURR_DSD Age/Sex: <1-9 2017 1,215
TX_CURR_DSD Age/Sex: 10-14 Female 2017 1,971
TX_CURR_DSD Age/Sex: 10-14 Male 2017 1,697
TX_CURR_DSD Age/Sex: 15-19 Female 2017 2,482
TX_CURR_DSD Age/Sex: 15-19 Male 2017 766
TX_CURR_DSD Age/Sex: 20-24 Female 2017 11,417
TX_CURR_DSD Age/Sex: 20-24 Male 2017 5,112
TX_CURR_DSD Age/Sex: 25-49 Female 2017 33,256
TX_CURR_DSD Age/Sex: 25-49 Male 2017 18,404
TX_CURR_DSD Age/Sex: 50+ Female 2017 2,482
TX_CURR_DSD Age/Sex: 50+ Male 2017 1,278
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 2,697
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 2,390
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 49,637
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 25,560
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 80,284
TX_CURR_DSD Sum of age/sex disaggregates 2017 3,248
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 5,087
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 75,197
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 80,284
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 635
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 564
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 12,158
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 6,266
TX_NEW_DSD By Age/Sex: <1 2017 45
TX_NEW_DSD By Age/Sex: 1-9 2017 288
TX_NEW_DSD By Age/Sex: 10-14 Female 2017 465
TX_NEW_DSD By Age/Sex: 10-14 Male 2017 401
TX_NEW_DSD By Age/Sex: 15-19 Female 2017 609
TX_NEW_DSD By Age/Sex: 15-19 Male 2017 188
TX_NEW_DSD By Age/Sex: 20-24 Female 2017 2,796
TX_NEW_DSD By Age/Sex: 20-24 Male 2017 1,254
TX_NEW_DSD By Age/Sex: 25-49 Female 2017 8,146
TX_NEW_DSD By Age/Sex: 25-49 Male 2017 4,509
TX_NEW_DSD By Age/Sex: 50+ Female 2017 607
TX_NEW_DSD By Age/Sex: 50+ Male 2017 315
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 19,623
TX_NEW_DSD Sum of Age/Sex disaggregates 2017 19,290
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 19,623
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 1,894
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 1,677
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 35,157
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 18,117
TX_PVLS_DSD Denominator: Indication: Routine 2017 56,845
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 56,845
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 51,162
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 1,703
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 1,508
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 31,637
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 16,314
TX_PVLS_DSD Numerator: Indication: Routine 2017 51,162
TX_RET_DSD Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 18
TX_RET_DSD Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20
TX_RET_DSD Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 136
TX_RET_DSD Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 121
TX_RET_DSD Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 187
TX_RET_DSD Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 165
TX_RET_DSD Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 215
TX_RET_DSD Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 192
TX_RET_DSD Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 206
TX_RET_DSD Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 185
TX_RET_DSD Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 262
TX_RET_DSD Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 233
TX_RET_DSD Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 949
TX_RET_DSD Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 847
TX_RET_DSD Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,744
TX_RET_DSD Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 48
TX_RET_DSD Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,763
TX_RET_DSD Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,461
TX_RET_DSD Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,276
TX_RET_DSD Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,587
TX_RET_DSD Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 208
TX_RET_DSD Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 180
TX_RET_DSD Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 434
TX_RET_DSD Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,891
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 255
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 226
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 303
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 270
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,126
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,673
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8,716
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7,759
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 11,928
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 13,400
VMMC_CIRC_DSD By Age: 10-14 2017 50,142
VMMC_CIRC_DSD By Age: 15-19 2017 37,278
VMMC_CIRC_DSD By Age: 20-24 2017 18,001
VMMC_CIRC_DSD By Age: 25-29 2017 10,285
VMMC_CIRC_DSD By Age: 30-49 2017 10,285
VMMC_CIRC_DSD By Age: 50+ 2017 2,567
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2017 128,558
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 128,558
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2017 128,558
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2017 107,988
Cross Cutting Budget Categories and Known Amounts Total: $400
Human Resources for Health $100
Key Populations: MSM and TG $150
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW $150
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs